Research graph
References from Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups. Local targets link to admitted publications; unresolved targets remain external evidence.
20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
10.1056/nejmoa1701830 · 2017 · External reference
Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2024.0035 · 2024 · External reference
21-Gene assay to inform chemotherapy benefit in node-positive breast cancer
10.1056/nejmoa2108873 · 2021 · External reference
Overall survival with abemaciclib in early breast cancer
10.1016/j.annonc.2025.10.005 · 2026 · External reference
10.1200/jco.23.01994
10.1200/jco.23.01994 · 2024 · External reference
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)
10.1200/jco.20.02514 · 2020 · External reference
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
10.1016/s1470-2045(22)00694-5 · 2023 · External reference
201P abemaciclib (abema) combined with adjuvant endocrine therapy (ET) in patients from monarchE in Asia with high-risk early breast cancer (EBC)
10.1016/j.esmoop.2025.104755 · 2025 · External reference
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data
10.1016/j.esmoop.2025.106021 · 2026 · External reference
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
10.1371/journal.pone.0264637 · 2022 · External reference
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
10.1016/j.annonc.2022.03.006 · 2022 · External reference
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study
10.1038/s41523-024-00639-1 · 2024 · External reference
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer
10.1016/j.annonc.2025.09.141 · 2026 · External reference
